BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag

Biogen (BIIB) announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, BIIB080.How Does the Fast Track Tag Benefit BIIB’s Drug Development?Fast track designation is designed to facilitate the development and expedite the review of drugs that treat serious conditions, fill an unmet medical need, or offer a potential advantage over existing treatments. Per the FDA, the purpose of granting this designation is to ‘get important new drugs to the patient earl ...